Font Size: a A A
Keyword [HER2-positive]
Result: 41 - 60 | Page: 3 of 6
41. The Role And Mechanism Of EPHA5 In The Trastuzumab Resistance Of HER2-positive Breast Cancer
42. Optimized Metformin And Trastuzumab Dosing Schedule Based On Circadian Dynamics Of Glucose Metabolism Overcome Trastuzumab Resistance In HER2-positive Gastric Cancer
43. 99mTc-ZHER2:V2 Molecular Imaging And Its Value In Monitoring The Early Efficacy In HER2 Positive Tumors' Treatment
44. Membrane Cholesterol Decreased Chemotherapy Sensitivity In HER2-positive Trastuzumab Resistant Gastric Cancer Via Upregulation Of ABCB1
45. The Effect And Mechanism Of Aqueous Extract Of Myrrh On Proliferation,Migration,Invasion Of HER2-Positive Breast Cancer Cells SK-BR-3
46. Expression Of MTDH,topo? In Pre-operative Neoadjuvant Chemotherapy Combined With Herceptin In Patients With HER2-positive Breast Cancer And Investigate The Prognosis
47. Targeted Therapy Effect Of ZHER2:V2-pemetrexed For HER2-positive Lung Adenocarcinoma And It's Molecular Imaging Evaluation
48. Involvement Of ER Stress In Mechanism Of Trastuzumab Resistance Occurrence And Transmission Of HER2-positive Gastric Cancer
49. The Molecular Mechanism And Clinical Significance Of MICA/B Expression In HER2-positive Breast Cancer
50. Target Agents On First Line Therapy Of Advanced HER2-positive Breast Cancer:A Network Meta-analysis
51. Detection Of HER2 Positive Circulating Tumor Cell By Using Anti-HER2-renilla Luciferase Fusion Protein
52. Preoperative Dose-dense Chemotherapy Or Postoperative Chemotherapy For Operative Triple Negative Or HER2-positive Breast Cancer:A Randomized Study
53. Different Expression Of Long-non Coding RNA In Her2 Positive Gastric Cancer
54. HER2 Positive Bilateral Metachronous Primary Breast Carcinoma: A Case Report And Literature Review
55. Study On The Mechanism Underlying Valproic Acid Reversed Trastuzumab Resistance In HER2-positive Breast Cancer Cells
56. The Analysis Of Diagnosis And Treatment In HER2 Positive Breast Cancer
57. Therapeutic Evaluation Of HER2-positive Breast Cancer With Neoadjuvant Chemotherapy Combined With Targeted Therapy
58. Trastuzumab Treatment After Progression In HER2-positive Metastatic Breast Cancer Following Relapse Of Trastuzumab-based Regimens
59. Prognostic Analysis Of HER2 Positive Metastatic Breast Cancer And Establishment Of Prognostic Model
60. The Expression And Heterogeneity Analysis Of PD-1/PD-L1 In Triple-negative Breast Cancer And The Clinical Significance Of TIL
  <<First  <Prev  Next>  Last>>  Jump to